Skip to main content

A Nurse’s Guide to the Changing Times in DLBCL & Practicalities of Antibody Therapy

April 16, 2021

Brought to you by PeerView Institute

During the current management era for diffuse large B-cell lymphoma (DLBCL), the emergence and validation of novel antibody-based therapies has offered patients a variety of effective therapeutic options that may be tailored to certain disease characteristics or a specific patient’s therapeutic needs, particularly those who relapse and are not candidates for autologous stem cell transplantation. As the healthcare providers closest to patients, oncology nurses and advanced practice clinicians are critical to the delivery of safe, high quality care with unique antibody options. 

This NCPD/ILNA-certified “Nurse Clinical Consults” symposium held during the ONS 46th Annual Congress will utilize a series of case and clinical vignettes to explore the essential role of oncology nurses in the management of DLBCL and the role of novel antibodies. Throughout, the expert nurse panelists will deliver expert guidance on topics such as educating patients on the clinical role of and efficacy expectations with novel antibodies; understanding safety considerations, such as infusion reactions, myelosuppression, and infections; and counseling patients on appropriate dosing and treatment schedules. Join us on April 27, 2021 at 9:00 AM EDT to hear essential evidence and practical guidance that can inform everyday nursing care for patients with DLBCL!  

Blog category